Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (181-190 of 343) with videos related to

Pageof 35
Sort By:
British Journal of Haematology|February 27, 2018
The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphomaBrady E Beltran, Denisse Castro, Jhony A De La Cruz-Vargas, et al.
Leukemia & Lymphoma|February 1, 2013
Extranodal marginal zone lymphoma of the cranial dura mater: report of three cases and systematic review of the literatureBrady E Beltrán, Benjamin Kuritzky, Pilar Quiñones, et al.
Blood|April 18, 2020
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patientsSteven P Treon, Jorge J Castillo, Alan P Skarbnik, et al.
Haematologica|April 21, 2018
True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosisAvinainder Singh, Hallie I Geller, Kevin M Alexander, et al.
British Journal of Haematology|January 10, 2023
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinibShayna Sarosiek, Joshua N Gustine, Catherine A Flynn, et al.
American Journal of Hematology|December 28, 2017
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM reboundJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
British Journal of Haematology|March 14, 2018
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2018
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström MacroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
British Journal of Haematology|May 10, 2017
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemiaJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
Leukemia & Lymphoma|October 31, 2017
Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?Brady E Beltran, Pilar Quiñones, Gadwyn Sanchez, et al.
Pageof 35

Showing results (181-190 of 343) with videos related to

Sort By:
Pageof 35
British Journal of Haematology|February 27, 2018
The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphomaBrady E Beltran, Denisse Castro, Jhony A De La Cruz-Vargas, et al.
Leukemia & Lymphoma|February 1, 2013
Extranodal marginal zone lymphoma of the cranial dura mater: report of three cases and systematic review of the literatureBrady E Beltrán, Benjamin Kuritzky, Pilar Quiñones, et al.
Blood|April 18, 2020
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patientsSteven P Treon, Jorge J Castillo, Alan P Skarbnik, et al.
Haematologica|April 21, 2018
True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosisAvinainder Singh, Hallie I Geller, Kevin M Alexander, et al.
British Journal of Haematology|January 10, 2023
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinibShayna Sarosiek, Joshua N Gustine, Catherine A Flynn, et al.
American Journal of Hematology|December 28, 2017
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM reboundJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
British Journal of Haematology|March 14, 2018
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2018
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström MacroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
British Journal of Haematology|May 10, 2017
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemiaJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
Leukemia & Lymphoma|October 31, 2017
Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?Brady E Beltran, Pilar Quiñones, Gadwyn Sanchez, et al.
Pageof 35